Wire Stories
Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
TOKYO–(BUSINESS WIRE)–Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter �Solasia�) and Nippon Kayaku Co., Ltd. (TOKYO:...